Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I study to evaluate the safety of concurrent chemoradiation combining
radiotherapy (IGRT) with two cytotoxic agents, capecitabine and oxaliplatin in patients with
advanced or inoperable hepatocellular carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Sanofi